256 related articles for article (PubMed ID: 34612768)
1. Chaperonin containing TCP1 subunit 3 (CCT3) promotes cisplatin resistance of lung adenocarcinoma cells through targeting the Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) pathway.
Danni X; Jiangzheng Z; Huamao S; Yinglian P; Changcheng Y; Yanda L
Bioengineered; 2021 Dec; 12(1):7335-7347. PubMed ID: 34612768
[TBL] [Abstract][Full Text] [Related]
2. Integrated analyzes identify CCT3 as a modulator to shape immunosuppressive tumor microenvironment in lung adenocarcinoma.
Huang J; Hu B; Yang Y; Liu H; Fan X; Zhou J; Chen L
BMC Cancer; 2023 Mar; 23(1):241. PubMed ID: 36918801
[TBL] [Abstract][Full Text] [Related]
3. Elevated Glutathione Peroxidase 2 Expression Promotes Cisplatin Resistance in Lung Adenocarcinoma.
Du H; Chen B; Jiao NL; Liu YH; Sun SY; Zhang YW
Oxid Med Cell Longev; 2020; 2020():7370157. PubMed ID: 32215178
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of CCT3 predicts poor prognosis and promotes cell proliferation via inhibition of ferroptosis and activation of AKT signaling in lung adenocarcinoma.
Wang K; He J; Tu C; Xu H; Zhang X; Lv Y; Song C
BMC Mol Cell Biol; 2022 Jun; 23(1):25. PubMed ID: 35773623
[TBL] [Abstract][Full Text] [Related]
5. PRDM14 mediates chemosensitivity and glycolysis in drug‑resistant A549/cisplatin cells and their progenitor A549 human lung adenocarcinoma cells.
He S; Ma X; Zheng N; Wang G; Wang M; Xia W; Yu D
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33355367
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC.
Hu Y; Hong Y; Xu Y; Liu P; Guo DH; Chen Y
Apoptosis; 2014 Nov; 19(11):1627-36. PubMed ID: 25213670
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
[TBL] [Abstract][Full Text] [Related]
8. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
9. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-204 deregulation in lung adenocarcinoma controls the biological behaviors of endothelial cells potentially by modulating Janus kinase 2-signal transducer and activator of transcription 3 pathway.
Liu X; Gao X; Zhang W; Zhu T; Bi W; Zhang Y
IUBMB Life; 2018 Jan; 70(1):81-91. PubMed ID: 29281186
[TBL] [Abstract][Full Text] [Related]
11. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
12. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
Pan X; Chen Y; Shen Y; Tantai J
Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576
[TBL] [Abstract][Full Text] [Related]
14. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
[TBL] [Abstract][Full Text] [Related]
15. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
16. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
17. lncRNA RP11-838N2.3 Promoted Cisplatin Resistance in Lung Adenocarcinoma.
Chen J; Jiang F; Hu L; Zhang F; Wang J; Huang K; Wang Y
Biomed Res Int; 2020; 2020():2806042. PubMed ID: 32626737
[TBL] [Abstract][Full Text] [Related]
18. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
19. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
[TBL] [Abstract][Full Text] [Related]
20. An inverse interaction between
Zhang Y; Yuan Y; Li Y; Zhang P; Chen P; Sun S
Epigenetics; 2019 Oct; 14(10):949-960. PubMed ID: 31144606
[No Abstract] [Full Text] [Related]
[Next] [New Search]
